Antiphospholipid antibody in XXXX .

@entity1 @entity650 @entity75 @entity2631 @entity1151 @entity3459 @entity4555 @entity33870 @entity785
OBJECTIVE: To investigate the prevalence and clinical correlation of antiphospholipid antibodies in @entity2631 . METHODS: Antibodies against cardiolipin (aCL) or beta(2)-glycoprotein I were examined by enzyme linked immunosorbent assay (ELISA) in 48 @entity1 with @entity2631 (18 @entity1 with @entity33870 , 20 with @entity2631 , and 10 with morphoea). Twenty one of these @entity1 were investigated for @entity4555 ( @entity4555 ) by screening and @entity3459 tests. RESULTS: @entity1 with @entity33870 , the severest form of @entity2631 , had significantly raised levels of IgM or IgG aCL relative to normal controls (n=21) and @entity1 with @entity785 (n=20). The IgM isotype was predominant, with the frequency of IgM aCL (61%) higher than that of IgG aCL (28%). Levels of aCL were similar for @entity1 with @entity2631 or morphoea and normal controls. IgM aCL were associated with a greater number of lesions, especially @entity75 , wider distribution of lesions, and the presence of immunological abnormalities including antinuclear antibodies, rheumatoid factor, IgM antihistone antibodies, IgG anti-single stranded DNA antibodies, and raised serum @entity650 levels in @entity1 with @entity2631 . @entity4555 was detected in 5/7 (71%) @entity1 with @entity33870 . However, @entity1151 was seen in only one @entity1 with @entity33870 . None of @entity1 with @entity2631 exhibited anti-beta(2)-glycoprotein I antibodies. CONCLUSIONS: These results suggest that aCL and @entity4555 are the major autoantibodies in @entity1 with @entity33870 .
